Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy

Cell Rep Med. 2025 Sep 16;6(9):102324. doi: 10.1016/j.xcrm.2025.102324. Epub 2025 Sep 1.

Abstract

The detailed mechanisms underlying the regulatory significance of dietary components in modulating anti-tumor immunity remain largely unknown. Here, we apply a co-culture-based screening approach using a blood nutrient compound library and identify zeaxanthin (ZEA), a dietary carotenoid pigment found in many fruits and vegetables and known for its role in eye health, as an immunomodulator that enhances the cytotoxicity of CD8+ T cells against tumor cells. Oral supplementation with ZEA, but not its structural isomer lutein (LUT), enhances anti-tumor immunity in vivo. Integrated multi-omics mechanistic studies reveal that ZEA promotes T cell receptor (TCR) stimulation on the CD8+ T cell surface, leading to improved intracellular TCR signaling for effector T cell function. Hence, ZEA treatment augments the efficacy of anti-PD1 immune checkpoint inhibitor in vivo and the cytotoxicity of human TCR gene-engineered CD8+ T cells in vitro. Our findings uncover a previously unknown immunoregulatory function of ZEA, which has translational potential as a dietary element in bolstering immunotherapy.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes* / drug effects
  • CD8-Positive T-Lymphocytes* / immunology
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunotherapy* / methods
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Antigen, T-Cell / metabolism
  • Zeaxanthins* / pharmacology

Substances

  • Zeaxanthins
  • Receptors, Antigen, T-Cell